We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical … expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is … the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital …

I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I …-2006. The estimates imply that chemotherapy innovation accounted for at least one-sixth of the decline in French cancer …

generics and their market shares. This relationship is stronger for pharmaceuticals under reference pricing rather than …

-sample of off-patent products. First, we construct a vertical differentiation model to analyze the impact of regulation on … several off-patent molecules before and after the policy reform. Off-patent drugs not subject to RP serve as our control group …

We construct a tractable general equilibrium model of cumulative innovation and growth, in which new ideas strictly … improve upon frontier technologies, and productivity improvements are drawn in a stochastic manner. The presence of positive … lower than the social planner's benchmark, which suggests a role for patent policy. We focus on a “non-infringing inventive …

This paper develops a model of patent trolls to understand various litigation strategies employed by nonpracticing …

patentability standards at PTOs (Patent and Trademark Offices awarding so-called bad patents), not only “false innovators” have the … chance of being granted patents but also, and more interestingly, “true innovators” are forced to patent more intensively … distortions caused by bad patents. Moreover, we show that introducing a two-tiered patent system is unlikely to improve market …